Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alfonso Calvo

Showing results (131-140 of 145) with videos related to

Pageof 15
Sort By:
Signal Transduction and Targeted Therapy|June 12, 2025
Dual ENPP1/ATM depletion blunts DNA damage repair boosting radioimmune efficacy to abrogate triple-negative breast cancerBorja Ruiz-Fernández de Córdoba, Karmele Valencia, Connor Welch, et al.
Journal of Immunology (Baltimore, Md. : 1950)|November 4, 2011
Pilot clinical trial of type 1 dendritic cells loaded with autologous tumor lysates combined with GM-CSF, pegylated IFN, and cyclophosphamide for metastatic cancer patientsCarlos Alfaro, Jose L Perez-Gracia, Natalia Suarez, et al.
Journal for Immunotherapy of Cancer|August 24, 2022
Spatially resolved proteomic profiling identifies tumor cell CD44 as a biomarker associated with sensitivity to PD-1 axis blockade in advanced non-small-cell lung cancerMyrto K Moutafi, Magdalena Molero, Sandra Martinez Morilla, et al.
Cell Death & Disease|November 3, 2024
G9a/DNMT1 co-targeting inhibits non-small cell lung cancer growth and reprograms tumor cells to respond to cancer-drugs through SCARA5 and AOX1Francisco Exposito, Miriam Redrado, Diego Serrano, et al.
Cancer Research|July 25, 2025
Dasatinib Remodels the Tumor Microenvironment and Sensitizes Small Cell Lung Cancer to ImmunotherapyEsther Redin, Nerea Otegui, Mirentxu Santos, et al.
Cancer Research|June 13, 2023
PTEN Loss Confers Resistance to Anti-PD-1 Therapy in Non-Small Cell Lung Cancer by Increasing Tumor Infiltration of Regulatory T CellsFrancisco Exposito, Miriam Redrado, Maeva Houry, et al.
Cancers|October 31, 2020
Id1 and PD-1 Combined Blockade Impairs Tumor Growth and Survival of <i>KRAS</i>-mutant Lung Cancer by Stimulating PD-L1 Expression and Tumor Infiltrating CD8<sup>+</sup> T CellsIosune Baraibar, Marta Roman, María Rodríguez-Remírez, et al.
Plos One|January 30, 2014
Identification of tissue microRNAs predictive of sunitinib activity in patients with metastatic renal cell carcinomaCelia Prior, Jose Luis Perez-Gracia, Jesus Garcia-Donas, et al.
International Journal of Cancer|March 9, 2019
Identification of mutations associated with acquired resistance to sunitinib in renal cell cancerMohamed Elgendy, Juan Pablo Fusco, Victor Segura, et al.
Nature Cancer|February 5, 2022
Short-term starvation reduces IGF-1 levels to sensitize lung tumors to PD-1 immune checkpoint blockadeDaniel Ajona, Sergio Ortiz-Espinosa, Teresa Lozano, et al.
Pageof 15

Showing results (131-140 of 145) with videos related to

Sort By:
Pageof 15
Signal Transduction and Targeted Therapy|June 12, 2025
Dual ENPP1/ATM depletion blunts DNA damage repair boosting radioimmune efficacy to abrogate triple-negative breast cancerBorja Ruiz-Fernández de Córdoba, Karmele Valencia, Connor Welch, et al.
Journal of Immunology (Baltimore, Md. : 1950)|November 4, 2011
Pilot clinical trial of type 1 dendritic cells loaded with autologous tumor lysates combined with GM-CSF, pegylated IFN, and cyclophosphamide for metastatic cancer patientsCarlos Alfaro, Jose L Perez-Gracia, Natalia Suarez, et al.
Journal for Immunotherapy of Cancer|August 24, 2022
Spatially resolved proteomic profiling identifies tumor cell CD44 as a biomarker associated with sensitivity to PD-1 axis blockade in advanced non-small-cell lung cancerMyrto K Moutafi, Magdalena Molero, Sandra Martinez Morilla, et al.
Cell Death & Disease|November 3, 2024
G9a/DNMT1 co-targeting inhibits non-small cell lung cancer growth and reprograms tumor cells to respond to cancer-drugs through SCARA5 and AOX1Francisco Exposito, Miriam Redrado, Diego Serrano, et al.
Cancer Research|July 25, 2025
Dasatinib Remodels the Tumor Microenvironment and Sensitizes Small Cell Lung Cancer to ImmunotherapyEsther Redin, Nerea Otegui, Mirentxu Santos, et al.
Cancer Research|June 13, 2023
PTEN Loss Confers Resistance to Anti-PD-1 Therapy in Non-Small Cell Lung Cancer by Increasing Tumor Infiltration of Regulatory T CellsFrancisco Exposito, Miriam Redrado, Maeva Houry, et al.
Cancers|October 31, 2020
Id1 and PD-1 Combined Blockade Impairs Tumor Growth and Survival of <i>KRAS</i>-mutant Lung Cancer by Stimulating PD-L1 Expression and Tumor Infiltrating CD8<sup>+</sup> T CellsIosune Baraibar, Marta Roman, María Rodríguez-Remírez, et al.
Plos One|January 30, 2014
Identification of tissue microRNAs predictive of sunitinib activity in patients with metastatic renal cell carcinomaCelia Prior, Jose Luis Perez-Gracia, Jesus Garcia-Donas, et al.
International Journal of Cancer|March 9, 2019
Identification of mutations associated with acquired resistance to sunitinib in renal cell cancerMohamed Elgendy, Juan Pablo Fusco, Victor Segura, et al.
Nature Cancer|February 5, 2022
Short-term starvation reduces IGF-1 levels to sensitize lung tumors to PD-1 immune checkpoint blockadeDaniel Ajona, Sergio Ortiz-Espinosa, Teresa Lozano, et al.
Pageof 15